Caris Life Sciences, Inc.

CAI· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$16.32+4.15%

2026-08-03

Financials

Valuation Metrics

Caris Life Sciences, Inc.'s Market Cap is $4.61B. At end of 2025 it was $45.11B. Ranked #1457 of 3,112 in US market (top 47%), #501 of 1,445 on NASDAQ (top 35%), #81 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$4.61B	US#1,457/3,112 Sec#81/269
Revenue	$907M	US#1,989/3,112 Sec#56/269
Net Income	$34M	US#1,967/3,112 Sec#65/269
Total Assets	$1.16B	US#2,385/3,112 Sec#89/269
Net Assets	$593M	US#2,126/3,112 Sec#94/269
Value
P/E	135.76x	US#2,107/3,112 Sec#70/269
P/B	7.77x	US#2,474/3,112 Sec#185/269
P/S	5.08x	US#2,279/3,112 Sec#80/269
EV/EBITDA	40.42x	US#2,297/3,112 Sec#72/269
FCF Yield	2.68%	US#1,819/3,112 Sec#63/269
Profitability
ROE	5.73%	US#1,796/3,112 Sec#63/269
ROA	2.92%	US#1,414/3,112 Sec#61/269
Op. Margin	15.91%	US#1,176/3,112 Sec#48/269
Revenue Growth	78.78%	US#186/3,112 Sec#39/269
Financial Health
Debt Ratio	95.86%	US#1,043/3,112 Sec#167/269
Total Debt	$431M	US#1,885/3,112 Sec#63/269
FCF	$123M	US#1,579/3,112 Sec#56/269
Cash	$821M	US#791/3,112 Sec#37/269
Current Ratio	7.05x	US#339/3,112 Sec#111/269
Net Debt/EBITDA	-3.73x	US#95/3,112 Sec#6/269
Performance
1Y Return	-41.80%	US#2,927/3,112 Sec#238/269
1M Return	-10.82%	US#2,641/3,112 Sec#172/269
From 52W High	-61.60%	US#2,946/3,112 Sec#242/269
1Y MDD	-62.98%	US#2,787/3,112 Sec#224/269
Trading
Volume	4,861,058 shares	US#377/3,112 Sec#28/269
Trading Value	$79M	US#1,055/3,112 Sec#62/269
Per Share
EPS	$-0.04	US—/3,112 Sec—/269
BPS	$0.35	US#2,697/3,112 Sec#225/269